Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neladenoson bialanate - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Neladenoson bialanate - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 1067197

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Heart failure therapies; Nitriles; Pyridines; Pyrrolidines; Thiazoles
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic heart failure

Most Recent Events

  • 01 Apr 2020 Discontinued - Phase-II for Chronic heart failure in Portugal, Japan, Israel, Greece, Belgium, USA, Austria, Bulgaria, Spain, Poland, Italy, Germany, Netherlands (PO) (NCT04322253)
  • 25 Mar 2020 Bayer terminated a phase I trial due to cessation of development project for Neladenoson bialanate in Germany (NCT04322253)
  • 20 Jun 2018 Bayer completes a phase II trial in Chronic heart failure in USA, Austria, Germany, Bulgaria, Spain, Portugal, Greece, Belgium, Israel, Italy, Japan and Poland (PO) (NCT03098979)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top